Detalhe da pesquisa
1.
A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
Nature;
584(7821): 353-363, 2020 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32659783
2.
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
N Engl J Med;
385(21): 1941-1950, 2021 11 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34706189
3.
Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials.
J Hepatol;
79(4): 924-932, 2023 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37290591
4.
Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice.
J Hepatol;
79(5): 1129-1138, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37459920
5.
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
JAMA;
327(13): 1236-1246, 2022 04 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35285853
6.
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.
Liver Int;
39(10): 1868-1875, 2019 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31136052
7.
96â¯weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
J Hepatol;
68(4): 672-681, 2018 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29756595
8.
No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.
Antimicrob Agents Chemother;
62(10)2018 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30038044
9.
Differential restriction patterns of mRNA decay factor AUF1 during picornavirus infections.
J Gen Virol;
95(Pt 7): 1488-1492, 2014 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24722678
10.
Cellular mRNA decay protein AUF1 negatively regulates enterovirus and human rhinovirus infections.
J Virol;
87(19): 10423-34, 2013 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23903828
11.
Viral proteinase requirements for the nucleocytoplasmic relocalization of cellular splicing factor SRp20 during picornavirus infections.
J Virol;
87(5): 2390-400, 2013 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23255796
12.
Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study.
Future Virol;
2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38074312
13.
Antibody therapy reverses biological signatures of COVID-19 progression.
Cell Rep Med;
3(8): 100721, 2022 08 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35977462
14.
Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment.
J Virol Methods;
249: 189-193, 2017 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28923315
15.
Generation of Recombinant Polioviruses Harboring RNA Affinity Tags in the 5' and 3' Noncoding Regions of Genomic RNAs.
Viruses;
8(2)2016 Feb 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26861382
16.
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Lancet Gastroenterol Hepatol;
1(3): 196-206, 2016 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28404092
17.
An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus.
mBio;
6(4): e01044, 2015 Jul 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26199334
18.
Picornavirus modification of a host mRNA decay protein.
mBio;
3(6): e00431-12, 2012 Nov 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23131833